Phase II Study of Gemcitabine and Docetaxel in Recurrent Platinum Resistant Ovarian Cancer

REFERENCES

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 1996;334:1–6.
   PubMed Web of Science ®Google Scholar
• Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084–3092.
   PubMed Web of Science ®Google Scholar
• Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992;10:513–514.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Paraiso D, Cure H, Germann N, Lortholary A, Lucas V, Barats JC, Plaza J, Barletta H, Gouttebel MC, GINECO. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc Am Soc Clin Oncol 2002;21 (abstr 829).
   Google Scholar
• Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530–1533.
   PubMed Web of Science ®Google Scholar
• Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89–93.
   PubMed Web of Science ®Google Scholar
• Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S, Gynecologic Oncology Group. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006;101:436–440.
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;88:130– 135.
   PubMed Web of Science ®Google Scholar
• Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabine. Brit J Cancer 1997;75:869–877.
   PubMed Web of Science ®Google Scholar
• Zoli W, Ricotti L, Dal Susino M, Barzanti F, Frassineti GL, Folli S, Tesei A, Bacci F, Amadori D. Docetaxel and gemcitabine activitity in NSCLC cell lines and in primary cultures from human lung cancer. Brit J Cancer 1999;81:609–615.
   PubMed Web of Science ®Google Scholar
• Zupi G, Scarsella M, D'Angelo C, Biroccio A, Paoletti G, Lopez M, Leonetti C. Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther 2005;8:866–871.
   Google Scholar
• Rebattu P, Quantin X, Ardiet C, Morere JF, Azarian MR, Schuller-Lebeau MP, Pujol JL. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 2001;33:277–287.
   PubMed Web of Science ®Google Scholar
• Rischin D, Boyer M, Smith J, Millward M, Michael M, Bishop J, Zalcberg J, Davison J, Emmett E, McClure B. A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals Oncol 2000;11:421–426.
   PubMed Web of Science ®Google Scholar
• Cascinu S, Gasparini G, Catalano V, Silva RR, Pancera G, Morabito A, Giordani P, Gattuso D, Catalano G. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals Oncol 1999;10:1377–1379.
   PubMed Web of Science ®Google Scholar
• Spiridonidis CH, Laufman LR, Jones J, Rhodes VA, Wallace K, Nicol S. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol 1998;16:3866–3873.
   PubMed Web of Science ®Google Scholar
• Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Kreienberg R, Mayordomo JI, Antón A, Harrison M, Jones M, Carrasco E, Vaury AT, Frimodt-Moller B, Fumoleau P. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009;27:1753–1760.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824–2831.
   PubMed Web of Science ®Google Scholar
• Garcia AA, O'Meara A, Bahador A, Facio G, Jeffers S, Kim DY, Roman L. Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 2004;93:493–498.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group study. Ann Oncol 1996;7:361–364.
   PubMed Web of Science ®Google Scholar
• Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investig New Drugs 1992;10:239–253.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125. J Clin Oncol 1996;14:1545–1551.
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1–10.
   PubMedGoogle Scholar
• Harries M, Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 2002;3:537–545.
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron JF. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183–2193.
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clinl Oncol 2001;19:3312–3322.
   PubMed Web of Science ®Google Scholar
• Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner Jr DR, Marciniack M, Naumann RW, Secord AA. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:2811–2818.
   PubMed Web of Science ®Google Scholar
• Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W, NOGGO Study Group. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol 2002;13:1749–1755.
   PubMed Web of Science ®Google Scholar
• Murgia V, Sorio R, Griso C, Caffo O, Arcuri C, Ferro A, Caldara A, Scalone S, Arisi E, Galligioni E. Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer. Int J Gynecol Cancer 2010;20:953–957.
   PubMed Web of Science ®Google Scholar
• Verhaar-Langereis M, Karakus A, van Eijkeren M, Voest E, Witteveen E. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. Int J Gynecol Cancer 2006;16:65–70.
   PubMed Web of Science ®Google Scholar
• Polyzos A, Kosmas C, Toufexi H, Malamos N, Lagadas A, Kosmidis C, Ginopoulos P, Ziras N, Kandilis K, Georgoulias V. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res 2005;25:3559-3564.
   PubMed Web of Science ®Google Scholar
• van der Burg ME, de Wit R, van Putten WL, Logmans A, Kruit WH, Stoter G, Verweij J. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 2002;86:19–25.
   PubMed Web of Science ®Google Scholar
• Bolis G, Parazzini F, Scarfone G, Villa A, Amoroso M, Rabaiotti E, Polatti A, Reina S, Pirletti E. Paclitaxel vs. epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol 1999;72:60–64.
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C, ICON, AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099–2106.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28:3107–3114.
   PubMed Web of Science ®Google Scholar
• Itani Y, Hosokawa K, Ito K, Takeuchi S, Tabata T, Tsubamoto H, Fujita H, Akiyama M, Adachi S. A phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer. Anticancer Res 2009;29:1521– 1526.
   PubMed Web of Science ®Google Scholar